Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Life Technologies Corporation

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Life Technologies Corporation

Regulatory records
12
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 12 FDA records to the applicant name Life Technologies Corporation. The collection includes 1 510(k) clearance. It includes 1 original PMA approval. 7 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 2, 2025 to Nov 4, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code PQP appears in 11 of the 12 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P240040, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 7335 Executive Way, Frederick, MD, 21704. Recorded on P240040/S008, decision dated Nov 4, 2026.

Changes described in PMA records

P240040/S008: Oncomine Dx Express Test

The FDA recorded approval on 2026-11-04 for P240040/S008, a supplement to the Oncomine Dx Express Test held by Life Technologies Corporation. The supplement is classified as a real-time process submission with a recorded reason of change to design, components, specifications or materials. The device category is a next generation sequencing oncology panel for somatic or germline variant detection, under product code PQP in the pathology specialty.

The recorded scope is narrow: approval covers Genexus Dx Software Security Patch version 6.8.2.2, intended to address vulnerabilities discovered in the Genexus Dx Software. This is a software component change within the existing application, not a new approval of the whole test system, and the source does not describe analytical or clinical performance data, affected assay functions, or the nature of the vulnerabilities. Whether the patch alters test performance or requires customer action is not stated in the available record.

FDA approval-order wording

Approval for Genexus Dx Software Security Patch version 6.8.2.2 to address the vulnerabilities discovered on the Genexus Dx Software.

Nov 4, 2026 · Real-Time Process

P240040/S005: Oncomine Dx Express Test

This FDA record documents the September 9, 2026 approval of supplement S005 to PMA P240040 for Life Technologies Corporation. The supplement, filed under the Panel Track with a labeling-change reason, expands the approved indications for use to add a companion diagnostic indication. That indication covers detection of ERBB2/HER2 activating mutations, specified as single nucleotide variants in exons 18–21 within the tyrosine kinase domain plus exon 20 insertions, in patients with non-small cell lung cancer.

The changed item is the indications statement of the device, a next-generation sequencing oncology panel for somatic or germline variant detection under product code PQP and the Pathology specialty. The source statement links the added indication to identifying NSCLC patients who may benefit from treatment with HYRNUO (sevabertinib). This supplement modifies the existing P240040 approval rather than approving the whole system anew; the record does not describe the panel's other content, performance characteristics, or original scope beyond the identifier.

FDA approval-order wording

Approval to expand the indications for use to include a companion diagnostic (CDx) indication for the detection of ERBB2/HER2 activating mutations (SNVs in exons 18-21 within the tyrosine kinase domain and exon 20 insertions) in patients with non-small cell lung cancer (NSCLC) who may benefit from treatment with HYRNUO (sevabertinib).

Sep 9, 2026 · Panel Track

P160045/S052: Oncomine Dx Target Test

FDA’s recorded scope: approval for an increase in quality control sampling of components during the QC release process

Mar 4, 2026 · Special (Immediate Track)

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
Life Technologies Corporation510(k) clearanceOct 15, 2026FDA
Life Technologies CorporationPMA supplementSep 9, 2026FDA
Life Technologies CorporationPMA supplementJun 8, 2026FDA
Life Technologies CorporationPMA supplementMar 4, 2026FDA
Life Technologies CorporationPMA supplementNov 21, 2025FDA
Life Technologies CorporationPMA supplementNov 19, 2025FDA
Life Technologies CorporationPMA supplementOct 22, 2025FDA
Life Technologies CorporationPMA supplementOct 15, 2025FDA
Life Technologies CorporationPMA supplementAug 8, 2025FDA
Life Technologies CorporationPMA supplementAug 7, 2025FDA
Life Technologies CorporationPMA approvalJul 2, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.